+ All Categories
Home > Documents > Comment #2 on First-Line Helicobacter pylori Vonoprazan...

Comment #2 on First-Line Helicobacter pylori Vonoprazan...

Date post: 15-Jul-2020
Category:
Upload: others
View: 1 times
Download: 0 times
Share this document with a friend
3
Letter to the Editor Comment #2 on First-Line Helicobacter pylori Eradication with Vonoprazan, Clarithromycin, and Metronidazole in Patients Allergic to PenicillinDavide Giuseppe Ribaldone 1 and Marco Astegiano 2 1 Department of Medical Sciences, Division of Gastroenterology, University of Turin, C.so Bramante 88, 10126 Turin, Italy 2 Department of General and Specialist Medicine, Gastroenterology-U, Città della Salute e della Scienza di Torino, Italy Correspondence should be addressed to Davide Giuseppe Ribaldone; [email protected] Received 27 February 2018; Accepted 26 August 2018; Published 16 December 2018 Academic Editor: Tatsuya Toyokawa Copyright © 2018 Davide Giuseppe Ribaldone and Marco Astegiano. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Recently, Sue et al. published an open-label study, aiming to assess the ecacy of a 7-day rst-line Helicobacter pylori (H. pylori) eradication regimen with vonoprazan (VPZ), clari- thromycin (CAM), and metronidazole (MNZ), in patients with penicillin allergy [1]. In a letter to the editor, Kashani and Abadi raised several criticisms of this article [2]. The authors responded [3], but we want to focus on two not redundant points. Considering appropriate some considerations (already reported by Sue et al.), especially those of the lack of controls and of the small sample size, we do not agree with two points. First, in the letter, it is reported that the factors aecting the success rate of H. pylori therapy were not checked and, among those, smoking habits and alcohol-drinking habits were reported. About these factors, there is no universal agreement in the literature [4, 5] and guidelines [6] on their ability to predict a poor response. Second, Kashani and Abadi reported the need to evaluate CAM and MNZ resistance before deciding the appropriate treatment [2]. This is correct [7]; however, it should be highlighted that it is possible to obtain H. pylori eradication with VPZ-based therapy in 70.2% of patients in whom rabeprazole-based therapy (with the same antibiotics) has failed [8]. Thus, VPZ-based treatment shows a relatively high eradication rate against clarithromycin-resistant H. pylori. A plausible explanation is that, since VPZ and CAM are metabolized by CYP3A4, a combined treatment with these three drugs can delay their clearance permitting a prolonged and more potent eect. In addition, the strong and fast- acting acid inhibitory eect of VPZ allowed the antibiotics to eradicate H. pylori [9]. Nevertheless, the ecacy of VPZ has not been reported for the combination of VPZ, CAM, and MNZ. Regarding the comment of Kashani and Abadi on the need to evaluate MNZ resistance by susceptibility tests, we would highlight that this resistance, although highly preva- lent, can be partly overcome and is of secondary importance. Hence, the need to evaluate MNZ resistance patient-by- patient could not be useful. It would be better to know in a spe- cic population MNZ and CAM resistance rates and apply the recommendation of the more updated guidelines [6]. Disclosure The contents of this article are the sole responsibility of the author and necessarily represent personal perspective. Conflicts of Interest The authors declare that the research was conducted in the absence of any commercial or nancial relationships that could be construed as a potential conict of interests. Hindawi Gastroenterology Research and Practice Volume 2018, Article ID 5260358, 2 pages https://doi.org/10.1155/2018/5260358
Transcript
Page 1: Comment #2 on First-Line Helicobacter pylori Vonoprazan ...downloads.hindawi.com/journals/grp/2018/5260358.pdf · Letter to the Editor Comment #2 on “First-Line Helicobacter pylori

Letter to the EditorComment #2 on “First-Line Helicobacter pylori Eradication withVonoprazan, Clarithromycin, and Metronidazole in PatientsAllergic to Penicillin”

Davide Giuseppe Ribaldone 1 and Marco Astegiano2

1Department of Medical Sciences, Division of Gastroenterology, University of Turin, C.so Bramante 88, 10126 Turin, Italy2Department of General and Specialist Medicine, Gastroenterology-U, Città della Salute e della Scienza di Torino, Italy

Correspondence should be addressed to Davide Giuseppe Ribaldone; [email protected]

Received 27 February 2018; Accepted 26 August 2018; Published 16 December 2018

Academic Editor: Tatsuya Toyokawa

Copyright © 2018 Davide Giuseppe Ribaldone and Marco Astegiano. This is an open access article distributed under the CreativeCommons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided theoriginal work is properly cited.

Recently, Sue et al. published an open-label study, aiming toassess the efficacy of a 7-day first-line Helicobacter pylori (H.pylori) eradication regimen with vonoprazan (VPZ), clari-thromycin (CAM), and metronidazole (MNZ), in patientswith penicillin allergy [1]. In a letter to the editor, Kashaniand Abadi raised several criticisms of this article [2]. Theauthors responded [3], but we want to focus on two notredundant points.

Considering appropriate some considerations (alreadyreported by Sue et al.), especially those of the lack of controlsand of the small sample size, we do not agree with two points.First, in the letter, it is reported that the factors affecting thesuccess rate of H. pylori therapy were not checked and,among those, smoking habits and alcohol-drinking habitswere reported. About these factors, there is no universalagreement in the literature [4, 5] and guidelines [6] on theirability to predict a poor response.

Second, Kashani and Abadi reported the need to evaluateCAM and MNZ resistance before deciding the appropriatetreatment [2]. This is correct [7]; however, it should behighlighted that it is possible to obtain H. pylori eradicationwith VPZ-based therapy in 70.2% of patients in whomrabeprazole-based therapy (with the same antibiotics) hasfailed [8]. Thus, VPZ-based treatment shows a relatively higheradication rate against clarithromycin-resistant H. pylori. Aplausible explanation is that, since VPZ and CAM are

metabolized by CYP3A4, a combined treatment with thesethree drugs can delay their clearance permitting a prolongedand more potent effect. In addition, the strong and fast-acting acid inhibitory effect of VPZ allowed the antibiotics toeradicate H. pylori [9]. Nevertheless, the efficacy of VPZ hasnot been reported for the combination of VPZ, CAM, andMNZ. Regarding the comment of Kashani and Abadi on theneed to evaluate MNZ resistance by susceptibility tests, wewould highlight that this resistance, although highly preva-lent, can be partly overcome and is of secondary importance.Hence, the need to evaluate MNZ resistance patient-by-patient could not be useful. It would be better to know in a spe-cific populationMNZ andCAMresistance rates and apply therecommendation of the more updated guidelines [6].

Disclosure

The contents of this article are the sole responsibility of theauthor and necessarily represent personal perspective.

Conflicts of Interest

The authors declare that the research was conducted in theabsence of any commercial or financial relationships thatcould be construed as a potential conflict of interests.

HindawiGastroenterology Research and PracticeVolume 2018, Article ID 5260358, 2 pageshttps://doi.org/10.1155/2018/5260358

Page 2: Comment #2 on First-Line Helicobacter pylori Vonoprazan ...downloads.hindawi.com/journals/grp/2018/5260358.pdf · Letter to the Editor Comment #2 on “First-Line Helicobacter pylori

References

[1] S. Sue, N. Suzuki, W. Shibata et al., “First-line Helicobacterpylori eradication with vonoprazan, clarithromycin, and metro-nidazole in patients allergic to penicillin,” GastroenterologyResearch and Practice, vol. 2017, Article ID 2019802, 6 pages,2017.

[2] N. Kashani and A. Talebi Bezmin Abadi, “Comment on “First-line Helicobacter pylori eradication with vonoprazan, clarithro-mycin, and metronidazole in patients allergic to penicillin”,”Gastroenterology Research and Practice, vol. 2018, Article ID5173904, 3 pages, 2018.

[3] S. Sue, N. Suzuki, W. Shibata et al., “Response to: Comment on“First-line Helicobacter pylori eradication with vonoprazan,clarithromycin, and metronidazole in patients allergic to peni-cillin”,” Gastroenterology Research and Practice, vol. 2018, Arti-cle ID 8046838, 2 pages, 2018.

[4] S. Y. Liu, X. C. Han, J. Sun, G. X. Chen, X. Y. Zhou, and G. X.Zhang, “Alcohol intake and Helicobacter pylori infection: adose-response meta-analysis of observational studies,” Infec-tious Diseases, vol. 48, no. 4, pp. 303–309, 2015.

[5] D. B. Namiot, K. Leszczyńska, Z. Namiot, A. J. Kurylonek, andA. Kemona, “Smoking and drinking habits are important pre-dictors of Helicobacter pylori eradication,” Advances in MedicalSciences, vol. 53, no. 2, pp. 310–315, 2008.

[6] P. Malfertheiner, F. Megraud, C. A. O'Morain et al., “Manage-ment of Helicobacter pylori infection – the Maastricht V/Flor-ence Consensus Report,” Gut, vol. 66, no. 1, pp. 6–30, 2017.

[7] D. Y. Graham, S. Fagoonee, and R. Pellicano, “Increasing rolefor modified bismuth-containing quadruple therapies for Heli-cobacter pylori eradication,”Minerva Gastroenterologica Dieto-logica, vol. 63, pp. 77–79, 2017.

[8] T. Inaba, M. Iwamuro, T. Toyokawa, and H. Okada, “Letter:promising results of Helicobacter pylori eradication withvonoprazan-based triple therapy after failure of proton pumpinhibitor-based triple therapy,” Alimentary Pharmacology &Therapeutics, vol. 43, no. 1, pp. 179-180, 2016.

[9] X. Yang, Y. Li, Y. Sun et al., “Vonoprazan: a novel and potentalternative in the treatment of acid-related diseases,” DigestiveDiseases and Sciences, vol. 63, no. 2, pp. 302–311, 2018.

2 Gastroenterology Research and Practice

Page 3: Comment #2 on First-Line Helicobacter pylori Vonoprazan ...downloads.hindawi.com/journals/grp/2018/5260358.pdf · Letter to the Editor Comment #2 on “First-Line Helicobacter pylori

Stem Cells International

Hindawiwww.hindawi.com Volume 2018

Hindawiwww.hindawi.com Volume 2018

MEDIATORSINFLAMMATION

of

EndocrinologyInternational Journal of

Hindawiwww.hindawi.com Volume 2018

Hindawiwww.hindawi.com Volume 2018

Disease Markers

Hindawiwww.hindawi.com Volume 2018

BioMed Research International

OncologyJournal of

Hindawiwww.hindawi.com Volume 2013

Hindawiwww.hindawi.com Volume 2018

Oxidative Medicine and Cellular Longevity

Hindawiwww.hindawi.com Volume 2018

PPAR Research

Hindawi Publishing Corporation http://www.hindawi.com Volume 2013Hindawiwww.hindawi.com

The Scientific World Journal

Volume 2018

Immunology ResearchHindawiwww.hindawi.com Volume 2018

Journal of

ObesityJournal of

Hindawiwww.hindawi.com Volume 2018

Hindawiwww.hindawi.com Volume 2018

Computational and Mathematical Methods in Medicine

Hindawiwww.hindawi.com Volume 2018

Behavioural Neurology

OphthalmologyJournal of

Hindawiwww.hindawi.com Volume 2018

Diabetes ResearchJournal of

Hindawiwww.hindawi.com Volume 2018

Hindawiwww.hindawi.com Volume 2018

Research and TreatmentAIDS

Hindawiwww.hindawi.com Volume 2018

Gastroenterology Research and Practice

Hindawiwww.hindawi.com Volume 2018

Parkinson’s Disease

Evidence-Based Complementary andAlternative Medicine

Volume 2018Hindawiwww.hindawi.com

Submit your manuscripts atwww.hindawi.com


Recommended